Diagnosing Antibiotic Resistance Using Nucleic Acid Enzymes and Gold Nanoparticles.
other · Level V
Where this comes from
- Record sourced from PubMed, PMID 33970612.
- Also identified by DOI 10.1021/acsnano.0c09902.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
The rapid and accurate detection of antimicrobial resistance is critical to limiting the spread of infections and delivering effective treatments. Here, we developed a rapid, sensitive, and simple colorimetric nanodiagnostic platform to identify disease-causing pathogens and their associated antibiotic resistance genes within 2 h. The platform can detect bacteria from different biological samples (<i>i.e</i>., blood, wound swabs) with or without culturing. We validated the multicomponent nucleic acid enzyme-gold nanoparticle (MNAzyme-GNP) platform by screening patients with central line associated bloodstream infections and achieved a clinical sensitivity and specificity of 86% and 100%, respectively. We detected antibiotic resistance in methicillin-resistant <i>Staphylococcus aureus</i> (MRSA) in patient swabs with 90% clinical sensitivity and 95% clinical specificity. Finally, we identified <i>mecA</i> resistance genes in uncultured nasal, groin, axilla, and wound swabs from patients with 90% clinical sensitivity and 95% clinical specificity. The simplicity and versatility for detecting bacteria and antibiotic resistance markers make our platform attractive for the broad screening of microbial pathogens.
Medical subject headings
- Metal Nanoparticles
- Methicillin-Resistant Staphylococcus aureus
- Nucleic Acids
- Staphylococcal Infections